Editas Medicine (EDIT) news
Recent news
H&M: No indications data environment has been compromised
On June 4, 2025, H&M experienced a significant system failure that disrupted payment processing across its UK stores, leaving customers unable to complete purchases for several hours. The issue, which affected multiple locations including a London branch, was attributed to problems with the…
AInvest Wire · 3d agoEditas Medicine - To begin patient dosing in 2026, report initial data in Q1 2027
Editas Medicine Inc. (NASDAQ:EDIT) is preparing to initiate patient dosing for one of its key programs in 2026, with initial clinical data expected in the first quarter of 2027. This development marks a significant milestone for the company as it advances its pipeline in the field of genetic…
AInvest Wire · 7d agoEditas Medicine - Receives approval to initiate phase 1/2 trial of edit-401 in Australia
AInvest Wire · 7d agoEditas Medicine - Expects topline safety and efficacy data for edit-401 later in 2027
AInvest Wire · 7d agoEditas Medicine receives approval to initiate first-in-human clinical trial of edit-401 in patients with hyperlipidemia
AInvest Wire · 7d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.